Aarti Pharmalabs receives SBTi approval for science-based emission targets across all scopes

Aarti Pharmalabs Limited has received official approval from the Science Based Targets initiative (SBTi) for its science-based emission reduction targets. This validation covers Scope 1, Scope 2, and Scope 3 emissions, placing the company among a select group of Indian pharmaceutical firms with comprehensive SBTi-aligned goals.

The approval aligns Aarti Pharmalabs’ climate strategy with the Paris Agreement, aiming to limit global temperature rise to well below 2°C above pre-industrial levels and pursue efforts to limit warming to 1.5°C.

This milestone comes three years after the company’s demerger in 2022 and follows a structured process that included carbon footprint assessment, energy efficiency measures, and collaboration across its value chain. The Science Based Targets initiative is a globally recognized organization that supports companies in setting emissions reduction targets grounded in climate science.

According to the company, it will now focus on implementing low-carbon technologies, improving operational efficiency, and strengthening collaborations with stakeholders to meet its climate targets.

The approval is expected to support Aarti Pharmalabs in meeting future environmental regulations and addressing the increasing demand for sustainable practices across industries. It may also enhance the company’s appeal to environmentally focused partners and stakeholders.

Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com

[ad_1]

_{Images are for reference only.Images and contents gathered automatic from google or 3rd party sources.All rights on the images and contents are with their legal original owners.}

[ad_2]